VoxelLTS:0QDB 97 PS Ratio is 1.96 as of Jul. 01, 2026, which is 26% above its 10-year median of 1.55. GuruFocus rates LTS:0QDB with a GF Score™ of 97/100 and a GF Value™ of zł128.03. The stock has 2 warning signs investors should review. Among 200 Medical Diagnostics & Research companies, Voxel ranks better than 61.5% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Voxel's share price is zł109.00.
Voxel's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was zł55.52. Hence, Voxel's PS Ratio for today is 1.96.
The historical rank and industry rank for Voxel's PS Ratio or its related term are showing as below:
LTS:0QDB'
s PS Ratio Range Over the Past 10 Years
Min: 0.86 Med: 1.55 Max: 3.48
Current: 2.01
During the past 13 years, Voxel's highest PS Ratio was 3.48. The lowest was 0.86. And the median was 1.55.
LTS:0QDB's PS Ratio is ranked better than 61.5% of 200
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.815
vs LTS:0QDB: 2.01
Voxel's Revenue per Sharefor the
three
months ended in Mar. 2026 was zł14.97.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was zł55.52.
Warning Sign:
Voxel SA revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Voxel was 4.70% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 17.40% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 10.40% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 18.30% per year.
During the past 13 years, Voxel's highest 3-Year average Revenue per Share Growth Rate was 37.50% per year. The lowest was 4.70% per year. And the median was 13.90% per year.
Back to Basics: PS Ratio
Voxel (LTS:0QDB) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Voxel PS Ratio Related Terms
Voxel PS Ratio Historical Data
* Premium members only.
The historical data trend for Voxel's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Voxel's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Voxel PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Voxel's PS Ratio distribution charts can be found below:
* The bar in red indicates where Voxel's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Voxel's Share Price of today is zł109.00. Voxel's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł55.52.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Voxel (LTS:0QDB) has a PS Ratio of 1.96 as of Jul. 01, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Voxel and its competitors. This is 26% above median its historical median of 1.55. Over the past decade, Voxel's PS Ratio has ranged from 0.86 to 3.48. According to the industry distribution chart, Voxel ranks #77 out of 200 companies in the Medical Diagnostics & Research industry, placing it in the top 38.5%.
Is Voxel's PS Ratio too high?
Voxel's current PS Ratio of 1.96 is 26% above median its 10-year median of 1.55. Over the past 10 years, this metric has ranged from a low of 0.86 to a high of 3.48. The Medical Diagnostics & Research industry median PS Ratio is 2.82. Voxel's value of 1.96 is 30.4% below this industry median. Based on the distribution chart, Voxel ranks #77 out of 200 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Voxel has a GF Score™ of 97/100, reflecting its overall financial health beyond just this single metric.
How does Voxel's PS Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Voxel ranks #77 out of 200 companies for PS Ratio. This puts Voxel in the upper half of its industry. The industry median PS Ratio is 2.82. Voxel's value of 1.96 is 30.4% below this benchmark. Historically, Voxel's own PS Ratio has ranged from 0.86 to 3.48 over the past decade. While the company's 10-year median is 1.55 vs. the industry median of 2.82, Voxel has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Diagnostics & Research company?
The median PS Ratio among Medical Diagnostics & Research companies is 2.82, based on 200 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Voxel's current PS Ratio of 1.96 is 30.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Voxel and its competitors. For the Medical Diagnostics & Research industry, the median PS Ratio is 2.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Voxel's current PS Ratio is 1.96, which is 26% above median its own 10-year median of 1.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Voxel stock overvalued right now?
Voxel (LTS:0QDB) has a current PS Ratio of 1.96. The stock's GF Value™ is zł128.03, compared to a current price of zł109.00 — trading 14.9% below its estimated fair value. The current PS Ratio is 1.96, which is 26% above median its 10-year median of 1.55 and 30.4% below the Medical Diagnostics & Research industry median of 2.82. Voxel's overall GF Score™ is 97/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Voxel (LTS:0QDB), the current PS Ratio is 1.96 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Voxel (LTS:0QDB) Overvalued in 2026?
Based on GuruFocus' analysis, Voxel stock appears to be undervalued.
The current stock price of zł109.00 is trading 14.9% below its estimated GF Value™ of zł128.03.
Key valuation signals for LTS:0QDB:
PS Ratio: 1.96 (26% above median its 10-year median of 1.55)
GF Value™: zł128.03 vs. price of zł109.00 (14.9% below fair value)
Industry Position: 30.4% below the Medical Diagnostics & Research median (#77 of 200)
No single metric tells the full story. See the LTS:0QDB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Voxel SA is a network of diagnostic imaging laboratories created for patients and to increase access to high-quality tests. The company operates diagnostic imaging centers and laboratories and provides several services such as magnetic resonance imaging, computed tomography and positron emission tomography. It has 33 specialised laboratories in 21 cities throughout Poland.
97GF Score
Get the complete analysis for LTS:0QDB
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0QDB has been successfully added to your 
